Literature DB >> 17296595

Elevated factor XIII level and the risk of myocardial infarction in women.

Zsuzsanna Bereczky, Emilia Balogh, Eva Katona, István Czuriga, István Edes, László Muszbek.   

Abstract

Factor XIII (FXIII) activity and antigen levels were determined in 955 patients investigated by coronary angiography. Patients were sub-grouped according to the presence or absence of coronary sclerosis (CS+, CS-) and a positive history of myocardial infarction (MI+, MI-). In females, but not in males, adjusted FXIII activity and antigen levels were significantly elevated in the CS+MI+ group compared to in the CS+MI- group. FXIII levels in the upper tertile were associated with significantly increased risk of MI in females, but not in males.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17296595     DOI： 10.3324/haematol.10647

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  10 in total

Review 1.  Newly-Recognized Roles of Factor XIII in Thrombosis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

2.  Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients.

Authors:  László Balogh; Éva Katona; Zoltán A Mezei; Judit Kállai; Réka Gindele; István Édes; László Muszbek; Zoltán Papp; Zsuzsanna Bereczky
Journal:  Mol Cell Biochem       Date:  2018-02-26       Impact factor: 3.396

3.  Factor XIII B subunit polymorphisms and the risk of coronary artery disease.

Authors:  Zoltán A Mezei; Zsuzsanna Bereczky; Éva Katona; Réka Gindele; Emília Balogh; Szilvia Fiatal; László Balogh; István Czuriga; Róza Ádány; István Édes; László Muszbek
Journal:  Int J Mol Sci       Date:  2015-01-06       Impact factor: 5.923

Review 4.  Advances of Coagulation Factor XIII.

Authors:  Da-Yu Shi; Shu-Jie Wang
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

5.  Terminal Phase Components of the Clotting Cascade in Patients with End-Stage Renal Disease Undergoing Hemodiafiltration or Hemodialysis Treatment.

Authors:  Krisztina Pénzes; Boglárka Hurják; Éva Katona; Gergely Becs; József Balla; László Muszbek
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

6.  Functional and Structural Characterization of Nucleic Acid Ligands That Bind to Activated Coagulation Factor XIII.

Authors:  Nasim Shahidi Hamedani; Arijit Biswas; Oliver Rudan; Rosa Tönges; Carlotta Meyring; Fabian Tolle; Günter Mayer; Johannes Oldenburg; Jens Müller; Bernd Pötzsch
Journal:  J Clin Med       Date:  2021-02-10       Impact factor: 4.241

7.  Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients.

Authors:  Zsuzsa Bagoly; Barbara Baráth; Rita Orbán-Kálmándi; István Szegedi; Réka Bogáti; Ferenc Sarkady; László Csiba; Éva Katona
Journal:  Biomolecules       Date:  2021-02-25

8.  F13A1 Gene Variant (V34L) and Residual Circulating FXIIIA Levels Predict Short- and Long-Term Mortality in Acute Myocardial Infarction after Coronary Angioplasty.

Authors:  Lucia Ansani; Jlenia Marchesini; Gabriele Pestelli; Giovanni Andrea Luisi; Giulia Scillitani; Giovanna Longo; Daniela Milani; Maria Luisa Serino; Veronica Tisato; Donato Gemmati
Journal:  Int J Mol Sci       Date:  2018-09-14       Impact factor: 5.923

9.  Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients.

Authors:  Yusuke Sawai; Yuta Yamanaka; Shosaku Nomura
Journal:  Vasc Health Risk Manag       Date:  2020-04-01

10.  Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis.

Authors:  Roberta Gualtierotti; Francesca Ingegnoli; Massimo Boscolo; Samantha Griffini; Elena Grovetti; Massimo Cugno
Journal:  Adv Ther       Date:  2019-10-25       Impact factor: 3.845
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.